Effect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLC

PFS

Progression free survival (PFS), defined as the time from the date of first dose of osimertinib to the date of investigator-assessed disease progression or death from any cause during study. Subjects who have not progressed or died at the time of analysis will be censored at the time of the latest date of assessment

Time frame: Followed up 10 months after last subject in

T790M mutation testing time

Average turnaround time.

Time frame: Within 14 days after enrollment date

Treatment patterns

To assess by number of previous adopted/current/future therapies as recorded on the case report form

Time frame: Followed up 10 months after last patient in

Adverse events

To assess by number of adverse events as recorded on the case report form.

Time frame: Follow up 10 months after last patient in.

Adverse event intensity

To assess by intensity of adverse events as recorded on the case report form, which will be measured by CTCAE grade system

Time frame: Follow up 10 months after last patient in.

T790M mutation testing sample

To assess by proportion of testing samples types as recorded on the case report form.